Evidence map›Paper›PMID 35466111›Full record

ArticleClinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology2022

Add-on Cariprazine in Patients with Long-term Clozapine Treatment and Treatment Resistant Schizophrenia: Two Cases of Psychotic Deterioration and Pisa Syndrome.

Judith Weise, Georg Schomerus, Sven Speerforck

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Observational
  4. Pisa Syndrome Secondary to Drugs: A Scope Review.Geriatrics (Basel, Switzerland) · 2024
    Review
  5. Article
  6. Cariprazine - an Alternative Treatment for Clozapine-resistant Schizophrenia?Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2023
    Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Judith WeiseDepartment of Psychiatry and Psychotherapy, Leipzig University Medical Center, Leipzig, Germany.ORCID https://orcid.org/0000-0003-1048-7628
Georg SchomerusDepartment of Psychiatry and Psychotherapy, Leipzig University Medical Center, Leipzig, Germany.ORCID https://orcid.org/0000-0002-6752-463X
Sven SpeerforckDepartment of Psychiatry and Psychotherapy, Leipzig University Medical Center, Leipzig, Germany.ORCID https://orcid.org/0000-0002-9281-8461
Leipzig University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An increasing number of studies deal with medical options for treatment resistant schizophrenia. If no remission can be achieved with clozapine, a combination of antipsychotics can be considered. The combination of clozapine and cariprazine is rarely studied. Cariprazine is a partial agonist on dopamine D

Indexed as

CariprazineClozapinePisa syndromeSchizophreniaTreatment resistance

Identifiers

PMID35466111
PMCPMC9048019
OpenAlexW4224309320

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.